Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Futura Medical continues global expansion with Latin America announcement

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Thomas Warner from Proactive London after the pharmaceutical company announced another milestone in its global expansion efforts. Barder shares the news that the Futura has reached an agreement to expand its presence in Latin America. Initially, Futura Medical had been working with key markets in Mexico and Brazil, and their agreement with local partner M8 Pharmaceuticals confirmed their interest in expanding to the rest of Latin America. The deal follows others in markets around the world. Barder mentions that the company has received regulatory approval in Mexico and is preparing for its launch there, and they anticipate several more launches in the coming months. The company remains on track to execute up to 10 launches between now and the end of April. He acknowledges the frustration among shareholders due to the declining share price in recent months. He attributed this decline, in part, to macroeconomic factors and interest rate uncertainty. While the company is actively exploring ways to address this issue, Barder emphasises that the primary focus remains on product commercialisation and expansion. Despite the share price challenges, Barder says that Futura Medical maintains a robust balance sheet and is fully funded to support its ongoing growth initiatives. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 07, 2023 11:53 AM Eastern Standard Time

Video

Big and Growing Need for Senior Care: Empowering Family Caregivers to Get the Supportand Guidance They Deserve

YourUpdateTV

November marks National Family Caregivers Month, a time to bring attention to the challenges faced by those caring for aging parents. Recently, Tatyana Zlotsky, President of A Place for Mom (APFM), conducted a satellite media tour to share vital insights and tips for family caregivers navigating the world of senior care. A video accompanying this announcement is available at: https://youtu.be/dUjQA6H_26Y There is a big and growing need for senior care, as the number of seniors is rapidly increasing and is projected to reach over 80 million by 2040. Today, 41 million Americans are unpaid caregivers for seniors, most often the adult daughter or son of their aging parents. As the senior population grows, family caregivers face serious challenges. A Place for Mom issued its new State of Caregiving Survey, showing that an overwhelming majority or caregivers are physically, mentally, and financially at risk. 82% have had to make sacrifices to provide adequate care. Nearly all (96%) reported being emotionally drained, with more than half feeling this way often or all the time. And 75% who were employed prior to assuming the caregiver role said they have less time to focus on work or have had to quit their jobs altogether to provide care. “These findings reveal some of the hard truths being faced by caregivers as they struggle to care for their aging parents and loved ones,” said Zlotsky. “Navigating the process of finding the most suitable senior care is not easy. There are three important things to consider – care needs, costs, and lifestyle.” First is care needs. Zlotsky shared that as seniors face a variety of physical and mental challenges, they require more and more assistance with their Activities of Daily Living. A Place for Mom finds that nearly all seniors they work with need some daily support, and more than 40% need extra help associated with dementia. The second is costs. “Families need help to better understand senior living costs in their area and options on how to pay,” said Zlotsky. At A Place for Mom, two-thirds of the families they work with have shared that they do not feel prepared when it comes to senior care costs and need help to better understand options and how to pay. “Lastly, families want to find a place where their parents will feel right at home -- a warm environment that helps them experience joy and feel a sense of community,” said Zlotsky. “This is where amenities and activities play an important role in helping mom or dad with the transition.” A Place for Mom has a team of senior living advisors who help caregivers navigate this journey end to end, all at no cost to families. “We start with a simple but very important question: tell us about your mom, dad, aunt, or uncle,” said Zlotsky. The expert advisors then gather critical information ranging from mobility, medication, and bathing assistance to mom’s favorite meals and activities. They then match those needs with preferred options and budget in order to make personalized recommendations for home care or senior living options to best assist the family. For senior living specifically, A Place of Mom also serves as a concierge to help families set up tours, understand feedback, and support the moving process. Special benefits and resources for veterans and their families: There are more than 8 million veteran seniors in the U.S. And at A Place for Mom – the veteran community is critically important. In fact, more than 30% of the families A Place for Mom helps are veteran families. “Veterans and their spouses may qualify for the VA Aid & Attendance benefit to help pay for senior care,” said Zlotsky. However, A Place for Mom’s survey revealed that more than two-thirds of veteran families don’t know how to access this monetary benefit or even understand it. A Place for Mom expert advisors are knowledgeable about VA benefits for senior care and help families understand what benefits are available. Their advisors’ expertise has helped families secure more than $8 million in financial aid annually. To expand their impact and help more veteran seniors and their families, A Place for Mom is joining forces with USAA, the leading veterans organization for financial resources, with over 13M members. Visit aplaceformom.com to learn more about A Place for Mom’s services and connect with a local expert advisor. About Tatyana Zlotsky Tatyana Zlotsky is the President of A Place for Mom, Inc., the leading online platform connecting families searching for senior care with a team of expert, local advisors providing insight-driven, personalized solutions. In this role, Tatyana leads the sales and marketing teams and is responsible for delivering on the company’s mission to enable caregivers to make the best senior living decisions. Since joining, Tatyana has served in various leadership roles at A Place for Mom and has successfully helped to transform the brand and overall family experience, which helps over 300K families per year. Tatyana joined A Place for Mom from American Express, where she spent nine years driving digital transformation as the VP/GM of Acquisition and Digital Innovation and was responsible for driving revenue growth in the U.S. Small Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 07, 2023 10:42 AM Eastern Standard Time

Video

Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes

Kadimastem Ltd.

Kadimastem Ltd. (TASE:KDST), a clinical cell therapy company developing a cell therapy treatment for ALS and a potential cure for diabetes and its diabetic product development partner, the American company iTolerance Inc., have asked the FDA for a preliminary meeting (INTERACT) regarding the companies’ joint diabetes treatment in development, iTOL-102, which does not require continuous suppression of the immune system. The companies signed a collaboration agreement several months ago to co-develop cell technology as a potential cure for diabetes without the need for chronic immunosuppression and received a total grant of about US$1 million from the international BIRD fund. This is the first of a three-step process, with the goal of designing and commencing an FDA-approved clinical study of iTOL-102. The second step would be to submit a pre-IND application based on the feedback from the INTERACT meeting, followed by an IND application to begin clinical trials at locations worldwide. In May 2023, the companies announced their research collaboration agreement to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression and received a grant in the aggregate amount of US$1m (with a budget of about US$2 million) from the Binational Israel-U.S. Industrial R&D (BIRD) Foundation. As part of the agreement, the companies are considering expanding their cooperation and advancing the development of iTOL-102 which combines Kadimastem’s advanced cell product for the treatment of diabetes called IsletRx, and iTolerance’s iTOL-100 immunomodulatory technology. The purpose of the meeting would be to present the iTOL-102 development program and specifically discuss the chemistry, manufacturing and control (CMC) program, the definitive proof of concept study design in light of preliminary data, and general plans for non-clinical safety and clinical development. The parties intend to continue the development of the product and are even considering expanding the cooperation, for the benefit of product development, including through the establishment of a joint company in the United States. IsletRx is comprised of clinical-grade clusters of human pancreatic islet like cells (ILCs) with the ability to secrete insulin. IsletRx cells can detect the sugar levels in the body and produce the required amounts of insulin and glucagon, iTolerance will provide its platform technology (iTOL-100) intended to enable the transplantation of allogeneic cells without tissue matching and without the need for chronic treatments that suppress the immune system of the transplant recipient (immunosuppression). Kadimastem Chief Executive Officer Asaf Shiloni added, “The INTERACT meeting is an important step forward for this development program. We are dedicated to advancing this program and providing diabetic patients with a potential solution to live without the need for insulin injections.” Dr. Anthony Japour, Chief Executive Officer of iTolerance, commented, “We are pleased with the continued progress of our research collaboration with Kadimastem and look forward to meeting with the FDA. We believe that this collaboration has the potential to provide a much-needed, innovative cure for patients with Type 1 Diabetes and look forward to building on our continued momentum.” At Kadimastem we envision being a global leader in cell therapy.Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s or iTolerance’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the companies' activity, as well as developments in the general environment and external factors affecting the companies' activity. The companies’ results and achievements in the future may differ materially from any presented herein and the companies make no undertaking to update or revise such projection or estimate and do not undertake to update this document. This document does not constitute a proposal to purchase the companies' securities or an invitation to receive such offers. Investment in securities in general and in the companies in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 s.bazak@kadimastem.com iTolerance Media Contact Susan Roberts +1 202-779-0929 sr@roberts-communications.com Company Website https://www.kadimastem.com/

November 07, 2023 07:00 AM Eastern Standard Time

Image

Faron Pharmaceuticals initiates second phase of BEXMAB study

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical-stage biopharmaceutical company announced it has initiated Phase 2 of its BEXMAB Study of Bexmarilimab in HMA-failed myelodysplastic syndrome (MDS). MDS is a group of bone marrow disorders that results in an inability to produce enough healthy blood cells. Jalkanen starts by giving a brief summary of the company's hope for the BEXMAB study, before going on to reveal more information about its second phase. He highlights the significant advantage to Faron of the relatively small size of the next phase of the study, which saves the company money at a time when many of its competitors are suffering financially - something he describes as a "a big relief for all of us." He concludes by giving an overview of the company's financial position, highlighting the €7.1 million raised in late October in a share offering. He adds that "very intense" discussions with potential partners are ongoing. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 06, 2023 12:36 PM Eastern Standard Time

Video

News Release

Ondine Biomedical’s Steriwave platform seeing strong adoption

Ondine Biomedical Inc

Ondine Biomedical Inc president and chief technology officer Nicolas Loebel and Matt Ross, vice president of Sales and Marketing joined Steve Darling from Proactive to share exciting news regarding the expansion of Ondine's Steriwave nasal photodisinfection technology within the healthcare sector. Alberta Health Services has confirmed its decision to expand the use of Steriwave nasal photo-disinfection following promising data from its pilot introduction at the Mazankowski Alberta Heart Institute. The pilot project demonstrated significant reductions in surgical site infections following cardiac surgery. Ross provided more details about the successful pilot project and shared that the Royal Alexandra Hospital in Edmonton is set to implement Steriwave nasal photo-disinfection before performing 3,000 orthopedic surgeries over the next year. The interest from hospitals across Canada and internationally has been increasing, leading to faster adoption of the platform. Loebel also highlighted the latest data from Vancouver General Hospital and UBC Hospital, which showed a remarkable 66.5% reduction in spine surgery infection rates with the pre-surgical use of Steriwave. These findings were presented at the IP2023 Annual conference in Liverpool in October and have been accepted for publication in the Canadian Journal of Surgery. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

November 06, 2023 03:00 AM Eastern Standard Time

Video

News Release

Vivos Therapeutics agrees to nationwide distribution deal with in-home respiratory dealer Lincare

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to share news the company has signed a nationwide distribution agreement in the United States with Lincare, a prominent supplier of in-home respiratory therapy products and services catering to approximately 1.8 million patients. Huntsman highlighted that this agreement comes on the heels of a successful distribution pilot with Lincare, marking a significant milestone in Vivos' strategic approach to partnering with leading durable medical equipment companies in the United States. The collaboration with Lincare is a testament to the quality and potential of Vivos' devices in improving patient well-being. As part of the agreement, Vivos has granted Lincare a six-month exclusivity period to distribute certain designated Vivos devices. This exclusivity underscores the commitment of both companies to leveraging their expertise and resources for the benefit of patients seeking effective solutions for respiratory health and overall well-being. The agreement marks a critical step in the company's mission to provide innovative and effective solutions for respiratory health, ultimately improving the lives of millions of patients across the United States. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

November 03, 2023 01:51 PM Eastern Daylight Time

Video

PathAI Announces New NASH/MASH Advisory Network to Guide Evidence Generation and Regulatory Strategy for AI-Powered Digital Pathology Product Development

PathAI

PathAI, a leading provider of precision pathology solutions, today announced the formation of a new advisory network to inform the company’s vision to leverage AI-powered digital pathology to improve outcomes for individuals with non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH). According to the American Liver Foundation, approximately 2-5% of adults in the U.S. have NASH/MASH, a disease with no FDA-approved treatments currently available. Disease incidence has risen from 1.51% in 2010 to 2.79% in 2020. The American Liver Foundation predicts that by 2030, NASH/MASH will be the most frequent reason for liver transplants in the U.S., underscoring the severe impact of this disease. Given the burden of NASH/MASH and lack of available treatment options for patients, attention from industry and academia alike is increasing, with numerous clinical trials in progress to develop novel, efficacious therapies for patients. PathAI has worked closely with experts in the field of NASH/MASH for years, including leading researchers, academics, patient advocacy groups, regulatory bodies and biotechnology and pharma partners, contributing to the development of solutions for this challenging disease. Previously, this close collaboration with NASH/MASH subject matter experts led to the development and validation of AIM-NASH ™, a tool that promises to reduce the impact of pathologist scoring variability on clinical trial outcomes by assisting pathologists in grading and staging key histologic features of NASH/MASH 1,2,as well as NASH Explore ™, an AI-powered panel of more than 1000 quantitative Human Interpretable Features (HIFs) that spatially characterize NASH/MASH tissue biopsy microarchitecture at the zonal and cellular level from H&E whole slide images. Now, PathAI will build on that collaboration by bringing together a diverse group of stakeholders across academia, medicine, regulatory science, patient advocacy, and industry to inform the evolution of the company portfolio. The network’s first meeting was held in September and will be held quarterly moving forward. “Scoring liver biopsies by an expert pathologist is a crucial aspect of NASH/MASH clinical trials. However, this benchmark tool is limited both in the availability of liver pathologists and intra/inter-observer variability of their evaluation,” Pierre Bedossa, Professor of Pathology at Groupe Hospitalier Paris Nord and visiting professor at the Institute of Cellular Medicine at Newcastle University, and PathAI advisor, pointed out. “AIM-NASH developed by PathAI marks clearly a step forward. This tool alleviates some of the limitations by providing a trustworthy AI-based evaluation of liver biopsy functioning under pathologist supervision. Promising results of AIM-NASH in the context of NASH clinical trials strongly suggest that this tool may become essential to speed up drug evaluation and development for the benefit of patients.” Other members of the advisor network include: Stephen A. Harrison, medical director for Pinnacle Clinical Research and the president of Summit Clinical Research. Karoline Lackner, professor of pathology at the Medical University of Graz. Rohit Loomba, professor of medicine and director of hepatology at the University of California at San Diego. Romil Saxena, professor of pathology and laboratory medicine at Emory University School of Medicine and a diplomate of the American Board of Pathology. G. Mani Subramanian, founder, OrsoBio Chris Leptak, Senior Vice President; drugs and biologics at Greenleaf Health, Inc. “As a leader in digital pathology for liver diseases, we recognize the responsibility we have to advance the science towards effective treatments for NASH/MASH with cutting-edge technology,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “At the same time, we recognize that only by incorporating the ideas and expertise of the leading minds in MASH will we truly achieve our mutual goal of improving patient outcomes for MASH patients.” The PathAI team will be attending the American Association for the Study of Liver Diseases annual meeting November 10-14 in Boston. Schedule time to talk about how PathAI’s solutions can drive liver disease clinical development at our booth (# D3100) by emailing nash@pathai.com. Read more about PathAI’s robust AI-powered products for NASH, including AIM-NASH ™ and NASH Explore ™, on PathAI’s website. 1 Harrison et al., Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoholic Steatohepatitis, EASL poster 2022. 2 Shevell et al. Comparison of manual vs machine learning approaches to liver biopsy scoring for NASH and fibrosis: a post hoc analysis of the FALCON 1 study. AASLD poster 2021 AIM-NASH & NASH Explore are authorized for research use only. Not approved for diagnostic use. About PathAI PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and operates its CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 02, 2023 10:00 AM Eastern Daylight Time

Poolbeg Pharma "continuing its campaign to find a partner" for POLB001

Poolbeg Pharma PLC

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on clinical-stage biopharmaceutical company Poolbeg Pharma. Appiah starts by explaining the scale of the opportunity that Poolbeg is pursuing with its lead compound POLB001 in acute influenza, noting the estimated 3-5 million severe influenza cases globally per annum. The company is broadening its reach by expanding the compound into the oncology sector. Additionally, Appiah highlights Poolbeg's recent developments in the oral vaccine sector. The company's oral delivery platform is in the limelight following an announcement about their collaboration with an undisclosed NASDAQ-listed biopharma enterprise. The partnership aims to utilise Poolbeg's oral drug delivery technology to optimise drug formulations targeting metabolic conditions. Significantly, this venture could pave the way for Poolbeg to tap into the burgeoning market for GLP-1 injectable treatments for obesity and diabetes, which is expected to grow significantly in the coming years. For a comprehensive insight into Poolbeg Pharma PLC, Daniel Appiah's full research report is accessible via the link in the video. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 02, 2023 06:08 AM Eastern Daylight Time

Video

CK Life Sciences Presenting Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-targeting PRAME and PD-L1, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

CK Life Sciences Int'l., (Holdings) Inc.

HONG KONG SAR - Media OutReach - 1 November 2023 - CK Life Sciences Int'l., (Holdings) Inc. is presenting preclinical data for its investigational dual-antigen cancer vaccines, co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed death-ligand 1), on November 4 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California, USA. The investigational cancer vaccines evaluated in the preclinical study contain antigenic sequences of PRAME and PD-L1 intended to induce anti-cancer immune responses. PRAME is a cancer antigen highly expressed in many different types of cancers and has been associated with different oncogenic processes. PD-L1 represents one of the most important immune checkpoint antigens highly expressed on cancer cells to limit T-cell activation in the tumour microenvironment. "CK Life Sciences has a growing pipeline of cancer vaccines in various stages of development. The preclinical efficacy results of our dual-targeting PRAME/ PD-L1 cancer vaccines in liver cancer are promising and we hope to start clinical trials in the coming years," said Melvin Toh, Vice President & Chief Scientific Officer at CK Life Sciences. "Liver cancer is the second most common cause of cancer death in Asia and remains a major unmet medical need. We plan to investigate the PRAME/ PD-L1 dual-targeting cancer vaccines further in liver cancer and other cancer types known to over-express PRAME and PD-L1." DETAILS ON POSTER PRESENTATION: Abstract 1336: Authors: Session Date and Time In this preclinical study, we investigated whether dual-antigen cancer vaccines co-targeting PRAME and PD-L1 could suppress tumour growth in both prophylactic and therapeutic syngeneic mouse hepatocellular carcinoma (HCC) models. Two recombinant fusion protein vaccines comprised of PD-L1 and PRAME with or without GM-CSF were synthesised and formulated with a Toll-like receptor 9 agonist CpG oligodeoxynucleotide and aluminum hydroxide for vaccination. In the prophylactic tumour model study, the vaccines were administrated subcutaneously twice at a two-week interval before implantation of mouse HCC cells expressing PRAME, followed by weekly vaccination. In the therapeutic model study, the vaccines were administrated weekly into the animals after tumour cell implantation. Body weight and tumour volume were measured three times a week. All mice experienced a recoverable body weight loss without any abnormal behavior or reduction of activity after vaccination. In the prophylactic model (n=10 mice), both fusion protein vaccines significantly inhibited tumour growth, with 76.4% ( P<0.01 ) and 59.5% ( P<0.05 ) tumour growth inhibition (TGI) compared to control group, respectively. Importantly, there were some vaccinated mice without palpable tumour mass at the end of the study. These results were consistent with that found in the therapeutic model study (n = 10 mice), in which both vaccines significantly inhibited tumour growth, with 43.4% ( P<0.01 ) and 40.7% ( P<0.05 ) TGI, respectively, and prolonged animal survival compared to the control group (P<0.01). The results of this preclinical study clearly highlight the potential of simultaneously targeting PRAME and PD-L1 by fusion protein vaccination in cancer immunotherapy. DISCLAIMER This press release may contain forward-looking statements regarding the Group's research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements. All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int'l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information. REFERENCES [1] Gradecki S, Slingluff C, Gru A. J Cutan Pathol. PRAME expression in 155 cases of metastatic melanoma. Accessed at https://onlinelibrary.wiley.com/doi/10.1111/cup.13876. [2] Oyama K, Kanki K, Shimizu H, Kono Y, Azumi J, Toriguchi K, Hatano E, Shiota G. Gastrointest Tumors. Impact of preferentially expressed antigen of melanoma on the prognosis of hepatocellular carcinoma. Accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465675/. [3] Thongprasert S, Yang PC, Lee J, Soo R, Gruselle O, Myo A, Louahed J, Lehmann F, Brichard V, Coche T. Lung Cancer. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients. Accessed at https://pubmed.ncbi.nlm.nih.gov/27794402/. [4] Epping M, Hart A, Glas A, Krijgsman O, Bernards R. Br J Cancer. PRAME expression and clinical outcome of breast cancer. Accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527791/. [5] Ahmad S, Borch T, Hansen M, Andersen M. Cancer Immunol Immunother. PD-L1-specific T cells. Accessed at https://pubmed.ncbi.nlm.nih.gov/26724936/. CK Life Sciences Int'l., (Holdings) Inc. CK Life Sciences Int'l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in, products and assets which fall into three core categories - nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com. About PRAME PRAME is a protein commonly expressed by cancer cells, including melanoma (1), liver cancer (2), lung cancer (3) and breast cancer (4). PRAME contributes to the development and spread of cancer cells, and studies have shown that high levels of PRAME are associated with poor outcomes in cancer patients (2,4). In recent years, researchers have been exploring ways to target PRAME using immunotherapy, such as T-cell therapy and cancer vaccines, as a potential treatment for cancer. About PD-L1 PD-L1 is a protein expressed by certain immune cells and cancer cells. It plays a role in suppressing anti-cancer immune responses by binding to a receptor called programmed death-1 (PD-1) on T-cells, limiting the activation of T-cells, thereby helping cancer cells evade the immune system. Antibodies that can block the interaction of PD-L1 and PD-1 have been approved for the treatment of certain types of cancer. Recent studies have shown the presence of PD-L1-specific T-cells in both healthy individuals and cancer patients, which suggests that targeting PD-L1 with T-cell therapy or cancer vaccines could be a promising approach for cancer treatment (5). Contact Details CK Life Sciences Int'l., (Holdings) Inc. Wendy Tong Barnes +852 2122 2150 wendytb@ckah.com

November 01, 2023 09:06 PM Eastern Daylight Time

1 ... 49 50 51 52 53 ... 275